An interventional study of Sleepiz One+ in COPD, Hypertension and Sleep Apnea, sponsored by Sleepiz AG. Completed at 1 site in Switzerland. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-05-08.
Sponsored by Sleepiz AG · Not applicable, Interventional, and Other
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 99 studies in Pulmonary Disease, Chronic Obstructive with a site in Switzerland — 15 open to participants now, 20 under way, 2 of them phase 3. Pulmonary Disease, Chronic Obstructive · Switzerland.
Among the 99 studies in Pulmonary Disease, Chronic Obstructive with a site in Switzerland, this one is the 58th largest by enrollment of the 77 interventional ones that give a count, is one of 6 that started in 2023, is one of 46 with no phase, and was the 81st registered.
5,529 studies on the registry are indexed under Pulmonary Disease, Chronic Obstructive; 858 are open to participants now.
Browse Pulmonary Disease, Chronic Obstructive studies →15 of the 99 studies in Pulmonary Disease, Chronic Obstructive with a site in Switzerland are open now. Recruiting first, the newest first:
Matthias Wilhelm, MD · Sites in Switzerland
Ages 18+
University Hospital, Geneva · Sites in Switzerland
Ages 18+
Mona Lichtblau · Sites in Switzerland
Sanofi · Sites in Switzerland, United States, Argentina and 19 more countries
Ages 40–85
Medical University of Graz · Sites in Switzerland, Austria, United Kingdom
Ages 18+
A study can be open while its sites in Switzerland have not opened yet or have stopped. Only those recruiting at a site in Switzerland →
Of the 560 Pulmonary Disease, Chronic Obstructive studies recruiting now, 307 (55%) set no upper age limit and 82 (15%) stop at 75 or younger; 30 take children under 18; 88 take healthy volunteers.
This study: 18 Years and older · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
99 studies; the count open now beside each. This study's row is marked.
First in 2002; this study’s year is marked. 6 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 36 is below the median of 62 across 3,847 interventional studies indexed under Pulmonary Disease, Chronic Obstructive.
Median enrollment 74 across the 77 interventional studies, 128 across the 22 observational. Of the 71 that completed or were terminated, 20 (28%) have results posted.
This tab as a report to print or save as PDF → With an account.
35 of 99 have an industry lead sponsor. The 10 most frequent:
Sleepiz AG is the lead sponsor of 5 studies on the registry; 1 is open to participants now.
Sleepiz AG has 2 studies filed under Pulmonary Disease, Chronic Obstructive — fewer than ten, so there is no comparison to draw.
10 of the studies in Pulmonary Disease, Chronic Obstructive with a site in Switzerland that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05878769Phase 3Hoffmann-La RocheA Study to Evaluate the Long-Term Safety of Astegolimab in Participants With Chronic Obstructive Pulmonary Disease (COPD) | 2027-06-30 |
| NCT07262229Institut et Haute Ecole de la Santé la SourceSelf-management Digital Intervention to Promote Physical Activity in People Living With COPD | 2026-11 |
| NCT02065921Prof. Dr. Jörg LeuppiSwiss Chronic Obstructive Pulmonary Disease (COPD) Management Cohort | 2026-12 |
| NCT07102823Medical University of GrazClinical Registry for the Characterization of the 'Pulmonary Vascular Phenotype' in Patients With Chronic Obstructive Pulmonary Disease | 2026-12-30 |
| NCT05163600University of ZurichThe Acute Cardiorespiratory Response to Blood-flow Restricted Versus Traditional Exercise Training Regimens (CaRe BFR) | 2026-12-31 |
Add all 10 to your calendar (.ics) → With an account.
Among the 99 studies in Pulmonary Disease, Chronic Obstructive with a site in Switzerland, from their registry updates:
This tab as a report to print or save as PDF → With an account.
EtCO2, or exhaled carbon dioxide, is a non-invasive and commonly used measure for respiratory rate and function. It can be easily monitored using a device called a capnograph, which consists of a sensor that is placed near the patient's mouth or nose and a monitor that displays the concentration of carbon dioxide in the respiratory gases in real-time.
EtCO2 capnography is generally considered a reliable and accurate method for monitoring respiration and is often used as a gold standard for comparing the performance of other methods for measuring respiration.
Therefore, the primary aim of this study is to provide a thorough comparison of the performance of Sleepiz One+ and EtCO2 Capnography for measuring respiration rate, in healthy adults and patients suffering from chronic conditions (e.g. hypertension, COPD, asthma, diabetes), at rest in a clinical setting. Additionally, the performance of heart rate estimation will be evaluated against ECG.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Patients:
Healthy volunteers
Exclusion Criteria:
Patients
Healthy volunteers:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Each enrolled participant will undergo a simultaneous recording with the Sleepiz One+, Capnography device and cardiorespiratory polygraphy with reduced number of channels (ECG and REB only) to measure respiration rate at and heart rate at rest, while sitting and lying down on a bed.
Device: Sleepiz One+
In this study Sleepiz One+ will measure heart rate and respiration rate of a participant sitting or lying in different positions (right and left side, back, abdomen) on a bed. The recording will take around 35 minutes.
Respiration rate measurement accuracy per 60s epoch against visually scored capnography data, recorded on subjects lying down and resting on a bed.
Time frame: 60s
Plan to share: No
No publications or documents are linked to this record.
Ran from Feb 2023 to primary completion in Apr 2023, 1 month.
Of 88 industry-sponsored interventional studies with no phase under Pulmonary Disease, Chronic Obstructive, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 35. This study's 1 month is below that.
Counting every sponsor, half of 1,187 studies reached it within 22 months; a quarter within 10 and three quarters within 39.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Pulmonary Disease, Chronic Obstructive →
Sleepiz AG